drugset / Trial / NCT05100160

Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial)

NCT05100160

Phase 3 Withdrawn M.D. Anderson Cancer Center
Non-randomizedSingle-groupOpen-labelSupportive care

Summary

The aim of this study is to determine if the reduction in narcotic requirement following pulmonary resection with gabapentin is clinically significant when compared to the effect seen with placebo. We have defined clinically meaningful as a reduction by 30 Morphine equivalent doses (MED)

Timeline

Start
2021-09-15
Primary completion
2023-01-03
Completion
2023-01-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Gabapentin Small molecule Oral

Indications